Comparison of radioimmunoprecipitation with luciferase immunoprecipitation for autoantibodies to GAD65 and IA-2β
- Peter D. Burbelo1,
- Horoki Hirai2,
- Alexandra T. Issa1,
- Albert Kingman3,
- Ake Lernmark4,
- S-A. Ivarsson4,
- Abner L. Notkins (anotkins{at}mail.nih.gov)2 and
- Michael J. Iadarola (miadarola{at}mail.nih.gov)1
- 1Neurobiology and Pain Therapeutics Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892
- 2Experimental Medicine Section, Oral Infection and Immunity Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, 20892
- 3Biostatistics Core, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, 20892
- 4Department of Paediatrics, Malmö University Hospital. Lund University, Malmö, Sweden
Abstract
Objective: To compare the sensitivity and specificity of luciferase immunoprecipitation (LIPS) with radioimmunoprecipitation (RIP) for the measurement of autoantibodies to the type 1 diabetes (T1D) autoantigens glutamic acid decarboxylase 65 (GAD65) and IA-2β.
Research Design And Methods: Sera from 49 T1D patients and 100 non-diabetic controls from DASP-2007 were used to screen for autoantibodies to GAD65. An additional 200 T1D patients and 200 non-diabetic controls were used to validate the GAD65 results and screen for autoantibodies to IA-2β.
Results: LIPS showed equal sensitivity and specificity to RIP for detecting autoantibodies to GAD65 and IA-2β. Receiver operating characteristic analysis revealed that the detection of autoantibodies to GAD65 and IA-2β by LIPS and RIP were not statistically different.
Conclusion: The LIPS assay does not require the use of radioisotopes or in vitro transcription/translation and is a practical alternative at the clinical level for the RIP assay.
Footnotes
-
- Received October 19, 2009.
- Accepted January 12, 2010.
- Copyright © American Diabetes Association
